YA II PN, Ltd. should definitely do DD on NWBO before providing the best financing. Which experts should YA II PN, Ltd. reach first for consulting?
I would think the experts should be those who just published the paper on a rGBM trial run by the company which has YA II PN, Ltd as the only institutional investor. https://fintel.io/so/us/Nbio
Here is the paper about the trial run by NBIO. The two authors published several papers in which the keyword 'DCVax-L' was explicitly mentioned. Santosh Kesari was even among the coauthors in two papers about the p3 trial.
The longs are going to embrace for a great year of 2025!
A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases
Jose Carrillo, Jaya Mini Gill , Charles Redfern, Ivan Babic, Natsuko Nomura, Dhaval K. Shah, Sean Carrick, and Santosh Kesari
Santosh Kesari Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaA Phase 3 Prospective Externally Controlled Cohort Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead & Robert O. Dillman https://link.springer.com/article/10.1186/s13046-022-02552-6
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines Feng Lin, Emma Z. Lin, Misa Anekoji, Thomas E. Ichim, Joyce Hu, Francesco M. Marincola, Lawrence D. Jones, Santosh Kesari & Shashaanka Ashili https://link.springer.com/article/10.1186/s12967-023-04724-0
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead & Robert O. Dillman https://link.springer.com/article/10.1186/s13046-022-02552-6
Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma Piccioni DE 1, Duma CM2 , Kesari S3, LaRocca RV4, Aiken RD5 , Taylor TH6, Carrillo JA2,3 , Abedi M7, Nistor GI 8 , Keirstead HS8, Dillman RO6,8*, Bota DA 6 https://pdfs.semanticscholar.org/6782/affbff554b427e1b14fd13ff88af8da535ce.pdf
Therapeutic Immunization against Glioblastoma Virgil E. J. C. Schijns 1,2,3,*, Chrystel Pretto 2, Anna M. Strik 1, Rianne Gloudemans-Rijkers 1, Laurent Devillers 2, Denis Pierre 2, Jinah Chung 4, Manisha Dandekar 4, Jose A. Carrillo 5,6, Xiao-Tang Kong 4,5,6, Beverly D. Fu 4,6, Frank P. K. Hsu 4,5, Florence M. Hofman 7, Thomas C. Chen 8, Raphael Zidovetzki 9, Daniela A. Bota 4,5,6 and Apostolos Stathopoulos 1,2,3,8,1
AI
